biomarck is developing technology that utilizes targeted anti-Marcks technology for the treatment of Cancer and Acute Respiratory Distress Syndrome (ARDS)
Proud to be recognized for 2019 “30 Best Companies of the year” CIO Bulletin and 2018 Winner” and Best Pipeline of Promise”, BIO 2018
We recently presented at the 38th annual J.P. Morgan Healthcare Conference
Learn more about the conference | Pressbiomarck is a biopharmaceutical company with a patented technology platform. We utilize anti-MARCKS peptides in order to develop and license products targeted at difficult to treat diseases with unmet needs. We are located in Research Triangle Park, N.C..
Our company has a worldwide patented drug platform of over 100 peptides that inhibit the phosphorylation of the MARCKS protein, a well published primary mediator of an inflammatory cytokine release involved in respiratory disease and cancer progression.
Kenneth Adler is Professor in the Department of Molecular Biomedical Sciences at North Carolina State University in Raleigh, NC. He received his Ph.D. in Cell Biology from the University of Vermont College of Medicine in 1978, and remained at Vermont as a postdoctoral fellow and faculty member in the Department of Pathology until 1987, when he moved to North Carolina State University, where he became Professor in 1992. In 1998, he was named Alumni Distinguished Graduate Professor at NCSU. Dr. Adler has published over 120 papers, mostly in the areas of airway inflammation, mucus secretion and cancer. He is an inventor or co-inventor on 51 patents.
1.Anti-MARCKS Peptides Inhibit Lung Cancer Metastasis in Mice
2.Inhibition of Lung Cancer Metastasis in mice by inhaled aerosolized anti-MARCKS peptides
4.MARCKS Protein Inhibitors Attenuate Cancer Cell Migration/Metastasis
5.A Novel Predictor of Cancer Malignancy: Up-regulation of Myristoylated Alanine-Rich C Kinase
6.A peptide that inhibits function of Myristoylated Alanine-Rich
biomarck pharmaceuticals intends to support children with difficult to treat cancers such as Rhabdomyosarcoma and Neuroblastoma. This may be done by a compassionate use program under the Investigator IND of the treating hospital. This effort will be done in support of the concepts of non-profit organizations such as the Miami based Live Like Bella Foundation (Learn More) which supports children with cancer, their families and research into childhood cancer.
Biomarck has been awarded a succession of grants under the auspices of the National Institute of Health (NIH). These include a Phase I SBIR grant for $100,000 in 2003, a Phase II SBIR grant for $1,228,000 in 2004, a Phase III SBIR grant for $2,990,000 in 2006, a SBIR grant for $3,000,000 in 2014 and a STTR grant for $201,503 in 2014. The SBIR grant process involves review of data and proposed development plans by a group of experts in the respiratory field. Excellent priority scores from this review group and positive funding decisions support the fact that the respiratory community (scientific and clinical) is eager to support the development of BIO-11006 Inhalation Solution.
